Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paliperidone palmitate 3-month versus 1-month formulations in schizophrenia
2011-004889-15Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2012
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of paliperidone palmitate in schizophrenia (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage of subjects not relapsed at end of 48-week double-blind phase. Started Feb 2012; status: completed.
02
Drugs
paliperidone palmitate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2011-004889-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004889-15.